Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples